Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 4.97K
-0.46%+6.89%+27.52%+16.32% 233B
-1.65%+6.49%+3.88%-14.90% 154B
-0.74%-3.67%-19.74%+31.63% 134B
-2.78%-4.72%-53.38%-2.83% 73B
+0.47%+3.56%-15.04%-11.66% 52.24B
+1.24%+0.28%+12.61%+21.40% 51.75B
-3.62%+3.23%+28.62%+28.25% 44.91B
-0.30%+0.42%+36.97%+51.00% 40.35B
-0.70%+2.67%-0.38%+8.59% 33.8B
Average -0.89%+1.86%+2.34%+14.20% 90.71B
Weighted average by Cap. -1.00%+3.06%+3.79%+11.82%
Logo SpectraScience, Inc.
SpectraScience, Inc. is focused on developing its WavSTAT Optical Biopsy System (WavSTAT). The WavSTAT employs a risk technology that optically illuminates tissue in real-time to distinguish between normal and pre-cancerous or cancerous tissue. The Company has developed a technology platform to determine if tissue is normal, pre-cancerous or cancerous, without the need for a physical biopsy. The WavSTAT4 Optical Biopsy System operates by using cool, safe ultraviolet (UV) laser light to optically illuminate and analyze tissue, enabling the physician to make a diagnosis during endoscopy when screening for cancer and, if warranted, to begin immediate treatment during the same procedure. The WavSTAT4 uses laser-induced auto-fluorescence to obtain spectral information from tissue at the suspected site. The system is classified as a non-significant risk device, which transmits low-level UV laser light energy through an optical fiber to the tissue through the working channel of an endoscope.
Employees
7
  1. Stock Market
  2. Stocks
  3. SCIE Stock